Indaptus Therapeutics, Inc.2024财年第三财季实现净利润-3.07百万美元，同比增加21.68%

市场透视11-14

11月14日，Indaptus Therapeutics, Inc.（INDP.US）公布财报，公告显示公司2024财年第三财季净利润为-3.07百万美元，同比增加21.68%；其中营业收入为0.00美元，每股基本收益为-0.32美元。从资产负债表来看，Indaptus Therapeutics, Inc.（INDP.US）总负债2.24百万美元，其中短期债务103982.00美元，资产负债比为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483640658?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-14 08:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483640658","market":"us","top_or_hot":-1,"title":"Indaptus Therapeutics, Inc.2024财年第三财季实现净利润-3.07百万美元，同比增加21.68%","media":"市场透视","content":"<div>\n<p>11月14日，Indaptus Therapeutics, Inc.（INDP.US）公布财报，公告显示公司2024财年第三财季净利润为-3.07百万美元，同比增加21.68%；其中营业收入为0.00美元，每股基本收益为-0.32美元。从资产负债表来看，Indaptus Therapeutics, Inc.（INDP.US）总负债2.24百万美元，其中短期债务103982.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114080224a235596f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Indaptus Therapeutics, Inc.2024财年第三财季实现净利润-3.07百万美元，同比增加21.68%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndaptus Therapeutics, Inc.2024财年第三财季实现净利润-3.07百万美元，同比增加21.68%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 08:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114080224a235596f&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月14日，Indaptus Therapeutics, Inc.（INDP.US）公布财报，公告显示公司2024财年第三财季净利润为-3.07百万美元，同比增加21.68%；其中营业收入为0.00美元，每股基本收益为-0.32美元。从资产负债表来看，Indaptus Therapeutics, Inc.（INDP.US）总负债2.24百万美元，其中短期债务103982.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114080224a235596f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114080224a235596f&s=b","article_id":"2483640658","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114080224a235596f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483640658","pubTimestamp":1731542536,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月14日，Indaptus Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-3.07百万美元，同比增加21.68%；其中营业收入为0.00美元，每股基本收益为-0.32美元。从资产负债表来看，Indaptus Therapeutics, Inc.总负债2.24百万美元，其中短期债务103982.00美元，资产负债比为3.68，流动比率为3.43。机构评级：截至2024年11月14日，当前有2家机构对Indaptus Therapeutics, Inc.目标价做出预测，其中目标均价为8.50美元，其中最低目标价为5.00美元，最高目标价为12.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","INDP":"Indaptus Therapeutics, Inc."},"translate_title":"Indaptus Therapeutics, Inc. achieved net profit of-US $3.07 million in the third fiscal quarter of fiscal year 2024, a year-on-year increase of 21.68%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INDP":1,"LENZ":1},"content_text":"11月14日，Indaptus Therapeutics, Inc.（INDP.US）公布财报，公告显示公司2024财年第三财季净利润为-3.07百万美元，同比增加21.68%；其中营业收入为0.00美元，每股基本收益为-0.32美元。从资产负债表来看，Indaptus Therapeutics, Inc.（INDP.US）总负债2.24百万美元，其中短期债务103982.00美元，资产负债比为3.68，流动比率为3.43。机构评级：截至2024年11月14日，当前有2家机构对Indaptus Therapeutics, Inc.目标价做出预测，其中目标均价为8.50美元，其中最低目标价为5.00美元，最高目标价为12.00美元。公司简介：Indaptus Therapeutics Inc 是一家临床前生物技术公司，致力于开发一种系统管理的新颖和专利的抗癌和抗病毒免疫疗法。该公司开发了一个专有平台，利用细菌的天然能力来激活先天性和适应性细胞免疫途径。 该公司的临床前候选药物 Decoy20 能够在针对结直肠癌、肝细胞癌、胰腺癌和非霍奇金淋巴瘤模型的联合治疗中引发单药活性和持久的抗肿瘤反应。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483640658"}